Article

Ochsner Accountable Care Network Announces More Than 23M in Savings for Medicare Beneficiaries

2019 clinical performance improves the lives of 30,000 aging Louisianians.

The Ochsner Accountable Care Network, LLC (OACN) is pleased to report its 2019 performance results, which include a reduction in the expected cost of care by more than $23 million for 31,000 Medicare beneficiaries. The 2019 savings represented a 53% increase in savings per beneficiary (nearly $800 per patient) and an 81% increase in total savings over 2018.

This report marks OACN’s third consecutive year of successful clinical performance. Namely, the progress in chronic disease management and preventive health programs positively impacted the overall health of the elderly population throughout the region.

“The continued success of Ochsner Health Network (OHN) and OACN is a reflection of unparalleled collaboration and a shared vision of creating a healthier region,” said David Carmouche, MD, executive director, OACN. “Louisiana and Mississippi face significant and disproportionate healthcare challenges compared to the rest of the country, and our entire team of providers and staff proves ready to face them by finding solutions that improve the health, quality of life and cost of care for our elderly patients and community. Through the sharing of data, utilization of technology, and enhanced access and communication, we are making strides toward reducing Louisiana’s alarmingly poor health rankings and disparities among our most vulnerable population.”


Learn more.

Related Videos
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Nadine Barrett, PhD
Neil Goldfarb, GPBCH
Dr Bonnie Qin
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
dr carol regueiro
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo